17515-77-4

Basic information

• Product Name: 2-(Bromomethyl)-5-(trifluoromethyl)furan
• Synonyms: 2-(BROMOMETHYL)-5-(TRIFLUOROMETHYL)FURAN;2-(Bromomethyl)-5-(trifluoromethyl)furane;2-(Bromomethyl)-5-(trifluoromethyl)furan 97%;2-(Bromomethyl)-5-(trifluoromethyl)furan97%;Furan,2-(broMoMethyl)-5-(trifluoroMethyl)-
• CAS NO: 17515-77-4
• Molecular Formula: C₆H₄BrF₃O
• Molecular Weight: 228.99
• Product Categories: Furans, Benzofurans & Dihydrobenzofurans;Methyl Halides;Furans, Benzofurans & Dihydrobenzofurans;Methyl Halides
• Mol File: 17515-77-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 38 °C
• Flash Point: 59.2 °C
• Appearance: /
• Density: 1.693 g/cm³
• Vapor Pressure: 1.5E-08mmHg at 25°C
• Refractive Index: 1.476
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• CAS DataBase Reference: 2-(Bromomethyl)-5-(trifluoromethyl)furan(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Bromomethyl)-5-(trifluoromethyl)furan(17515-77-4)
• EPA Substance Registry System: 2-(Bromomethyl)-5-(trifluoromethyl)furan(17515-77-4)

Safety Data

• Hazard Codes: C
• Statements: 34-36/37/38-43
• Safety Statements: 26-36/37/39-45-36/37
• RIDADR: 1760
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 17515-77-4(Hazardous Substances Data)

Usage

Description

2-(Bromomethyl)-5-(trifluoromethyl)furan is an organic compound characterized by its furan ring structure, which features a bromomethyl group at the 2nd position and a trifluoromethyl group at the 5th position. 2-(Bromomethyl)-5-(trifluoromethyl)furan is known for its reactivity and versatility in chemical synthesis, making it a valuable building block in the development of various pharmaceuticals and other specialty chemicals.

Uses

Used in Pharmaceutical Industry:
2-(Bromomethyl)-5-(trifluoromethyl)furan is used as an intermediate for the preparation of tertiary sulfonamides, which serve as liver X receptor (LXR) antagonists. These LXR antagonists are important in the treatment of various metabolic disorders, such as dyslipidemia and atherosclerosis, by modulating the activity of liver X receptors and reducing the synthesis of cholesterol and triglycerides.
Additionally, 2-(Bromomethyl)-5-(trifluoromethyl)furan is utilized in the synthesis of hydantoin-based inhibitors of MMP13 (matrix metalloproteinase 13). These inhibitors have potential applications in the treatment of osteoarthritis, a degenerative joint disease characterized by the breakdown of cartilage and the underlying bone. By inhibiting MMP13, which is an enzyme involved in the degradation of cartilage, these compounds can help slow down the progression of osteoarthritis and alleviate associated pain and inflammation.

InChI:InChI=1/C14H15F6NO4S2/c1-25-12(22)11(3-4-26-2)21-27(23,24)10-6-8(13(15,16)17)5-9(7-10)14(18,19)20/h5-7,11,21H,3-4H2,1-2H3

Upstream product

• 17515-75-2 2-methyl-5-(trifluoromethyl)furan 

Downstream Products

• 1001096-25-8 C₂₁H₂₃F₃NO₅P 
• 1026790-86-2 3(R)-3-{[(1-phenylcycloheptyl)carbonyl]oxy}-1-{[5-(trifluoromethyl)-2-furyl]methyl}-1-azoniabicyclo[2.2.2]octane bromide 
• 1227622-89-0 1-{3-[5-bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-benzyl]-azetidin-1-yl}-2,2,2-trifluoro-ethanone 
• 1221277-90-2 GSK₂₀₃₃ 
• 444915-70-2 ethyl 3-(4-fluorophenyl)-3-oxo-2-((5-(trifluoromethyl)-2-furanyl)methyl)propionate 
• 1308380-88-2 ((R)-2-{3-(2-fluoro-6-trifluoromethyl-benzyl)-5-[3-hydroxymethyl-4-(5-trifluoromethyl-furan-2-ylmethyl)-piperazin-1-yl]-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl}-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 1308380-26-8 ((R)-2-{3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-5-[4-(5-trifluoromethyl-furan-2-ylmethyl)-piperazin-1-yl]-3,6-dihydro-2H-pyrimidin-1-yl}-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 1467104-81-9 3-[6-(benzyloxy)-1,3-benzodioxol-5-yl]-3-hydroxy-1-{[5-(trifluoromethyl)furan-2-yl]methyl}-1,3-dihydro-2H-indol-2-one 
• 1467104-82-0 3-[6-(benzyloxy)-1,3-benzodioxol-5-yl]-1-{[5-(trifluoromethyl)furan-2-yl]methyl}-1,3-dihydro-2H-indol-2-one 
• 1467104-87-5 (3S)-3-[6-(benzyloxy)-1,3-benzodioxol-5-yl]-3-[(benzyloxy)methyl]-1-{[5-(trifluoromethyl)furan-2-yl]methyl}-1,3-dihydro-2H-indol-2-one 
• 1259933-16-8 XEN-402 
• 1240494-86-3 N-(4-fluorophenyl)-6-((5-(trifluoromethyl)furan-2-yl)methylthio)nicotinamide 
• 1308378-34-8 1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-5-(4-((5-(trifluoromethyl)furan-2-yl)methyl)piperazin-1-yl)pyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

AMINOETHANOL DERIVATIVES

The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.